Table 2.

Patients’ post-operative outcome

Patient no.	Visual function	New permanent hormonal deficit	Surgical complication	Post-op RT	Tumour status	KPS	FU duration (months)	Remarks
1	Normal	DI, ↓ACTH	None	Yes	Tumour-free	90	109	None
2	Normal	None	None	No	Stable residue	90	104	Recurrence after previous transsphenoidal removal and RT
3	Normal	None	None	No	Tumour-free	90	105	Recurrence after previous transsphenoidal removal and RT
4	Normal	DI	None	Yes	Tumour-free	80	28	Died 28 months later from unrelated cause
5	Residual left HeAn	Panhypopituitarism	None	Yes	Stable residue	90	93	Biochemical remission with bromocriptine
6	Normal	None	CSF leakage	Yes	Stable residue	90	65	None
7	Normal	None	None	No	Stable residue	100	63	Patient refused RT
8	Improved BTH	None	None	No	Stable residue	80	55	Recurrence after previous transsphenoidal removal and RT
9	Normal	↓TSH	Deep vein thrombosis	Yes	Tumour-free	100	54	Deep vein thrombosis treated with caval filter.
10	Residual left HeAn	↓ACTH	None	Yes	Stable residue	100	24	None
11	Normal	None	None	No	Tumour-free	70	24	Patient refused RT
12	Normal	None	None	Yes	Stable residue	100	26	None

ACTH adrenocorticotropic hormone, BTH bitemporal hemianopia, CSF cerebrospinal fluid, DI diabetes insipidus, FU follow-up since surgery, HeAn hemianopia, KPS Karnofsky Performance Score, RT external radiotherapy, TSH thyrotropic stimulating hormone